# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target fr...
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of...
Wolfe Research analyst Andy Chen upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Peer Perform to Outperform.
Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target fr...
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.